What are the side effects of SS-31?

The review focuses on adverse event patterns reported in trials through 2024, explains mechanistic context that bears on safety expectations, and highlights limitations and areas where further data are needed. It does not provide therapeutic recommendations and should be combined with primary sources for protocol or clinical decision making.

What is SS-31 peptide and why safety matters

SS-31 peptide, also known by the generic name elamipretide, is a mitochondria-targeting tetrapeptide developed for research and clinical investigation into mitochondrial diseases and conditions where mitochondrial function is implicated. The compound was evaluated across a range of clinical programs and preclinical studies that focused on its ability to stabilize mitochondrial membranes and influence cellular energy handling.

The available safety information for this article comes primarily from clinical trial reports and preclinical mechanistic studies rather than broad postmarketing surveillance. Those trial and program summaries provide the most direct evidence about elamipretide tolerability, while mechanistic literature helps explain why specific patterns of side effects may appear in human studies. See our Peptides 101 resources. Stealth BioTherapeutics pipeline

At-a-glance: reported side effects of SS-31

Across randomized and open-label clinical trials, the most frequently reported side effects with SS-31 peptide included injection-site reactions, gastrointestinal complaints such as nausea, and neurological symptoms like headache and transient dizziness. These events were generally reported as mild to moderate in severity. For general peptide background see our peptides page.

Serious adverse events that investigators judged related to elamipretide were uncommon in phase 2 and phase 3 publications; many serious events reported during trials were attributed to underlying disease or other causes rather than the study drug. Peer reviewed trial summaries

Most common adverse events in detail

Injection-site reactions were the leading complaint in multiple programs, typically described as local redness, tenderness, or mild swelling following subcutaneous or intravenous dosing. Onset was usually within hours to days after administration and most instances resolved without specialized medical intervention.

Gastrointestinal complaints, particularly nausea, were also frequently reported. Trial narratives and safety tables describe nausea as transient in most participants, with occasional reports of brief vomiting or appetite changes; investigators typically managed these symptoms with supportive care. TAZPOWER and related trial records

Neurological symptoms recorded across programs were generally limited to headache and transient dizziness. These events were usually short lived and did not often require discontinuation of the study drug, although they were a common reason for symptomatic treatment or temporary observation in trial protocols.

Most common adverse events in detail – injection-site reactions

Injection-site reactions typically presented as localized discomfort, erythema, or small-area swelling at the administration site. Reports indicate that most reactions were mild and self limiting, with symptomatic measures such as local cooling or topical care used when needed.

Timing of onset and resolution varied by study and route of administration, but repeated dosing schedules did not consistently show increasing severity for most participants. When an injection-site reaction was pronounced, investigators often documented the event and managed it conservatively rather than stopping treatment immediately. Peer reviewed trial summaries

Most common adverse events in detail – gastrointestinal complaints

Nausea was commonly recorded across programs. Descriptions in trial reports emphasize its transient nature and note that most cases were managed without escalation of care. Anti emetics were used in some protocols as needed, but formal rules for prophylaxis were not universally reported.

Other GI observations included occasional vomiting and minor appetite changes. These complaints were typically recorded in trial adverse event tables as low grade and short duration. TAZPOWER and related trial records

Most common adverse events in detail – neurological symptoms

Headache was a frequently logged symptom and was usually mild to moderate, often responsive to standard analgesics. Dizziness or lightheadedness was reported intermittently and characterized as transient in most cases.

Neither headache nor transient dizziness commonly required permanent discontinuation of therapy, though trial investigators documented occurrences and treated them symptomatically when necessary. Integrated safety analyses

Serious adverse events and discontinuation rates

Published phase 2 and phase 3 studies reported that serious adverse events attributed directly to elamipretide were uncommon, with many SAE reports judged by investigators to reflect the underlying disease or intercurrent medical issues rather than a drug related cause. See the FDA integrated review for aggregated trial safety summaries: FDA integrated review

Overall trial discontinuation rates due to adverse events were generally low in the integrated summaries, but authors consistently cautioned that sample sizes and follow up durations limited the ability to detect rare or delayed safety signals. Integrated safety analyses

How SS-31 works and why that matters for side effects

Mechanistic studies indicate that SS-31 binds cardiolipin on the inner mitochondrial membrane and can reduce reactive oxygen species and mitigate mitochondrial structural dysfunction in preclinical models. This targeted mechanism provides a plausible basis for observed effects and helps explain why no dominant organ specific toxicity signal emerged across trials.

Because the peptide’s proposed activity centers on mitochondrial stabilization rather than direct interaction with a single organ system, the clinical safety pattern has been one of mainly systemic, usually mild or moderate adverse events rather than concentrated organ damage in published reports. Mechanistic studies See a mechanistic review at PMC11816484.

Clinical trial evidence by indication

Barth syndrome was studied in the TAZPOWER program, where investigators reported the expected pattern of mostly mild to moderate adverse events and few drug related serious events. Those records and summaries provide indication specific context that aligns with broader program safety findings.

Primary mitochondrial myopathy was evaluated in programs such as MMPOWER, which likewise reported frequent injection-site reactions and transient gastrointestinal or neurological complaints, with uncommon attribution of serious events to the study drug. Differences in population characteristics and study duration affect direct comparison across indications. TAZPOWER and related trial records See the NuPower registry entry at NCT05162768.

Heart failure programs and integrated safety summaries included participants with comorbid conditions and reported similar tolerability patterns, though patient baseline risk may have contributed to some serious events observed during those studies. Authors emphasize caution in extrapolating safety conclusions across markedly different clinical populations. Integrated safety analyses

Key limitations and evidence gaps

Most clinical programs to date enrolled small to moderate numbers of participants and followed them for months rather than years, which limits the ability to detect rare or late onset adverse events. This constraint is a common limitation when interpreting tolerability data from early phase and mid phase trials.

There is also limited published evidence on drug drug interactions and on outcomes in special populations such as pregnant people, children, or those with severe renal or hepatic impairment; these remain areas of higher uncertainty for safety assessment. Review and expert commentary

Special populations and potential interactions to watch

Published data on pregnancy and pediatric use are sparse, so these groups should be considered higher uncertainty settings. Formal safety characterizations for these populations were not established in the available trials and are not well represented in the integrated summaries. Review and expert commentary

Similarly, persons with severe renal or hepatic impairment were not a focus of most programs, and guidance on dose adjustment or altered monitoring in these situations is not available in a consistent, evidence based form. When research protocols include such participants, closer monitoring and conservative decision making are advised. Review and expert commentary

Drug drug interaction data for elamipretide remain limited, with no well documented pharmacokinetic interactions described in the pivotal integrated studies; nonetheless, combining the peptide with agents known to strongly affect mitochondrial function should prompt caution and consideration of enhanced monitoring. Integrated safety analyses

Practical management: monitoring and treating side effects

Management recommendations in the literature emphasize symptomatic care for common adverse events. For injection-site reactions, local measures and observation are typical first steps, while nausea and headache are generally managed with standard supportive measures used in trial protocols.

When clinically indicated, monitoring of renal and hepatic function is advised and documentation of all adverse events is important for later integrated safety reviews. Investigators and clinicians are encouraged to report unexpected findings to registries or sponsors to improve the evidence base. Stealth BioTherapeutics pipeline

Decision framework for researchers and clinicians

Weigh the existing tolerability data against study goals and participant risk. Given a consistent pattern of mainly mild to moderate events and uncommon drug related serious events in trials, the decision to include elamipretide in a protocol should factor in population vulnerability, monitoring capacity, and likely benefit within the research question.

Escalation criteria often used in trial practice include persistent or progressively worsening symptoms, new organ dysfunction, or any unexpected serious event; when such triggers occur, protocols typically call for pausing dosing, increasing monitoring, and reporting the event to the sponsor and relevant registries. Integrated safety analyses

Common errors, misinterpretations and what to avoid

A common mistake is generalizing tolerability from small trials to broad clinical safety. Small sample sizes and limited follow up can miss rare or late events, so absence of evidence in early programs should not be interpreted as proof of safety in all settings.

Another error is assuming mechanistic plausibility equates to clinical safety; while cardiolipin binding and mitochondrial stabilization are plausible mechanisms that help explain observed effects, mechanistic data do not replace careful clinical monitoring and reporting. Mechanistic studies

Concrete examples and scenarios

Sample 12 week monitoring schedule adapted from trial practice might include baseline metabolic and organ function labs, symptom checklists at each visit, and focused injection-site inspection after dosing. This template can be adapted to study needs but follows the pattern used in published programs. See our safety and legality guidance.

Example consent language can note the most commonly reported side effects, emphasize that serious drug related events were uncommon in trials to date, and clarify that longer term and rare risks remain incompletely characterized. Reporting an unexpected SAE should follow sponsor and registry procedures, with prompt documentation in source notes and safety databases. TAZPOWER and related trial records

Summary and next steps for readers

In summary, SS-31 peptide has a consistent safety profile in published trials through 2024 characterized mainly by mild to moderate injection-site reactions, nausea, headache and transient dizziness, with uncommon attribution of serious adverse events to the drug in phase 2 and phase 3 reports.

Key evidence gaps remain for rare events, long term safety, drug drug interactions and special populations; readers are encouraged to consult trial registries and integrated safety reviews for updates and to report unexpected events to improve the evidence base. Review and expert commentary

Frequently asked questions